Reduced numbers of circulating CD28-negative CD4+ cells in patients with rheumatoid arthritis chronically treated with abatacept

International Journal of Rheumatic Diseases

Volumn 16, Issue 4, 2013, Pages 469-471

  Gómez García, Lorena ^a   Ramírez Assad, Cecilia ^a   Vargas, Angelica ^a   Massó, Felipe ^a   Sánchez Muñoz, Fausto ^a   Márquez Velasco, Ricardo ^a   Amezcua Guerra, Luis M ^a   Bojalil, Rafael ^a,b  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIMALARIAL AGENT; CD28 ANTIGEN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA INTERFERON; I KAPPA B; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6;

ACUTE CORONARY SYNDROME; CD4+ T LYMPHOCYTE; CYTOKINE RELEASE; DAS28; FOLLOW UP; HUMAN; LETTER; LONG TERM CARE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIGENS, CD28; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CD4-POSITIVE T-LYMPHOCYTES; CELL COUNT; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84883465083     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12056     Document Type: Letter

References (9)

1. Lindstrom TM, Robinson WH (2010) Rheumatoid arthritis: a role for immunosenescence? J Am Geriatr Soc 58, 1565-75.
2. Martens PB, Goronzy JJ, Schaid D, Weyand CM (1997) Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum 40, 1106-14.
3. Gerli R, Schillaci G, Giordano A et al. (2004) CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 109, 2744-8.
4. Wells AF, Westhovens R, Reed DM et al. (2011) Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. J Rheumatol 38, 2362-8.
5. Scarsi M, Ziglioni T, Airò P (2010) Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. J Rheumatol 37, 911-6.
6. Choremi-Papadopoulou H, Viglis V, Gargalianos P, Kordossis T, Iniotaki-Theodoraki A, Kosmidis J (1994) Downregulation of CD28 surface antigen on CD4+ and CD8+ T lymphocytes during HIV-1 infection. J Acquir Immune Defic Syndr 7, 245-53.
7. Kern F, Ode-Hakim S, Vogt K, Hoflich C, Reinke P, Volk HD (1996) The enigma of CD57+CD28- T cell expansion-anergy or activation? Clin Exp Immunol 104, 180-4.
8. Liuzzo G, Biasucci LM, Trotta G et al. (2007) Unusual CD4+CD28null T lymphocytes and recurrence of acute coronary events. J Am Coll Cardiol 50, 1450-8.
9. Scarsi M, Ziglioli T, Airò P (2011) Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. J Rheumatol 38, 2105-11.